This content is from: Premium
Viking, Other Hedge Funds Eye Biopharma IPO
Investors may not be too excited about the new issues market, however.
A slew of hedge funds led by Viking Global Investors are gearing up for perhaps the first biopharma initial public offering of the year.Given 2021’s rough ride for IPOs, however, investor enthusiasm about new issues may not be very high, at least not for now. On Monday, Amylyx Pharmaceuticals, a biotech
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.